Cargando…

Clopidogrel resistance "Live" – the risk of stent thrombosis should be evaluated before procedures

Every year, millions of people undergo percutaneous coronary intervention (PCI) with intracoronary stent implantation. A patient from the PRAGUE-8 trial (Optimal pre-PCI clopidogrel loading: 600 mg before every coronary angiography vs. 600 mg in the cath-lab only for PCI patients) is described who s...

Descripción completa

Detalles Bibliográficos
Autores principales: Motovska, Zuzana, Widimsky, Petr, Marinov, Iuri, Petr, Robert, Hajkova, Jaroslava, Kvasnicka, Jan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693432/
https://www.ncbi.nlm.nih.gov/pubmed/19454028
http://dx.doi.org/10.1186/1477-9560-7-6
Descripción
Sumario:Every year, millions of people undergo percutaneous coronary intervention (PCI) with intracoronary stent implantation. A patient from the PRAGUE-8 trial (Optimal pre-PCI clopidogrel loading: 600 mg before every coronary angiography vs. 600 mg in the cath-lab only for PCI patients) is described who suffered from acute stent thrombosis. This patient did not have any relevant inhibition of platelet activation even after the 600 mg dose of clopidogrel. Dose uptitration would have been ineffective. New P2Y(12 )receptor inhibitors are desperately needed. In the light of recently published data, the use of prasugrel may be considered as an alternative.